Recor Medical’s renal denervation lowered blood pressure
Renal denervation using Recor Medical’s technology significantly reduced blood pressure among people with drug-resistant hypertension, another study reported.
The study news, announced yesterday, could suggest a turnaround in fortunes for renal denervation technology. One considered the next big thing in the medical device industry, renal denervation took a hit in the middle of the 2010s when Medtronic announced a major clinical trial had failed to meet its efficacy endpoint.
However, Medtronic has since sought trial designs that clear up confounding factors such as differing medication regimens and patient compliance. (Renal denervation study results involving Medtronic are expected out of EuroPCR tomorrow.) The ReCor-funded Radiance-HTN Trio study appears to have done the same, requiring all 989 people in the study upon enrollment to switch to a 3-in-1 combo blood pressure medication to better ensure adherence.
The randomized sham-controlled found a median reduction of 8.0 mmHg in daytime ambulatory systolic blood pressure after two months among those who had undergone a procedure with ReCor Medical’s Paradise ultrasound renal denervation system. The reduction was 4.5 mmHg greater than the drop experienced among those who had undergone a sham procedure. Learn more here.